Zenapax
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
rejection of kidney transplants
General Information
Hoffman-La Roche's new monoclonal antibody drug, Zenapax
(daclizumab), has been approved to prevent rejection of kidney
transplants. The drug uses the body's own immune system to
prevent the acute rejection that can make kidney transplants
fail.
Clinical Results
The FDA said its approval was based on two clinical trials that
showed Zenapax significantly reduced acute rejections in patients
who got the drug along with the standard three-drug cocktail of
immunosuppressant drugs. Patients on Zenapax had 37 to 40% fewer
rejections episodes than those given an inert placebo.
